Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 4 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Spinalcyte LLC has 8 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 7 distinct examiners and 4 distinct art units, indicating broad examiner dispersion alongside repeated activity in some examination units. Counsel should coordinate technical positions across the matters while adapting responses to the relevant examiner and unit.
MIANO, JOSEPH PAUL is the busiest examiner, with 2 pending matters. That assignment is the clearest point of examiner concentration in the listed data, although the portfolio otherwise involves multiple examination perspectives. Reviewing those matters together may help identify recurring issues before preparing separate responses.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 2 | 35.7% | +63.4% |
| JOHNSON, KARA D | 1 | 69.3% | +25.1% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17453143 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 52d overdue |
| 18905224 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | JOHNSON, KARA D | — |
| 18570530 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | ALDARONDO, DASIA ALI | — |
| 17996392 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | SCHUBERG, LAURA J | — |
| 17052845 | INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SINGH, ANOOP KUMAR | — |
| 16068096 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | CORDAS, EMILY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17453143 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 52d overdue |
| 17052841 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | 36d overdue |
| 18905224 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | JOHNSON, KARA D | — |
| 18345022 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | — |
| 17996392 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | SCHUBERG, LAURA J | — |
| 17052845 | INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SINGH, ANOOP KUMAR | — |
| 16068096 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | CORDAS, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1631 | 3 |
| 1647 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18905224 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | JOHNSON, KARA D | 1632 | §103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18570530 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | ALDARONDO, DASIA ALI | 1647 | §103§112DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18345022 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | 1631 | §103Other | Non-Final OA | — | Pending | Jun 30, 2023 |
| 17996392 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | SCHUBERG, LAURA J | 1631 | §102§103 | Final Rejection | — | Pending | Oct 17, 2022 |
| 17453143 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 1633 | §103§112 | Non-Final OA | 52d overdue | Pending | Nov 01, 2021 |
| 17052845 | INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 04, 2020 |
| 17052841 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | 1631 | §103Other | Final Rejection | 36d overdue | Pending | Nov 04, 2020 |
| 16068096 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | CORDAS, EMILY ANN | 1632 | §103§112 | Final Rejection | — | Pending | Dec 17, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpinalcyte LLC has 8 pending office actions as of October 2026, spread across 4 art units and 7 examiners.
Joseph Paul Miano has the most, with 2 of Spinalcyte LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
